Metastatic Colorectal Cancer Clinical Trials in Shanghai, Shanghai Municipality
5 recruitingShanghai, Shanghai Municipality, China
Showing 1–5 of 5 trials
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal CancerBRAF V600 Mutation
Fudan University100 enrolled1 locationNCT06749015
Recruiting
Phase 2
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.130 enrolled1 locationNCT06493760
Recruiting
Phase 2
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Metastatic Colorectal Cancer
Fudan University44 enrolled1 locationNCT05229003
Recruiting
Phase 1
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital78 enrolled1 locationNCT06225622
Recruiting
Phase 2
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Metastatic Colorectal Cancer
Fudan University101 enrolled1 locationNCT05970705